Quince Therapeutics, Inc. QNCX
31.00
1.00
3.33%
as of 25 Sep
- Market cap
- $30.5M
- P/E
- 0.0×
Follow QNCX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
1.12 | 0.53 | 2.92 | 14.52 |
Net Debt/EBITDA |
0.64 | (0.03) | 1.24 | 1.45 | |
Debt/Assets |
15.94% | 19.63% | 0.00% | 0.00% | |
Debt/Equity |
16.54 | (0.51) | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 0.27 | (0.21) | 0.25 | |
Capex/Depreciation |
0.37 | 0.03 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.62 | 0.73 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(37.07) | (41.86) | (16.73) | (3.08) | |
Cash per Share |
97.44 | 70.87 | 39.83 | 18.91 | |
Shareholders Equity per Share |
3.93 | (142.57) | 34.37 | (5.76) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.93 | (142.57) | 34.37 | (5.76) | |
Free Cash Flow |
(10.00) | (10.48) | (7.63) | (18.89) | |
Working Capital |
3.16 | (20.33) | 16.81 | 114.91 | |
Capital Expenditures |
(0.07) | 0.00 | — | — | |
Net Current Asset Value |
(79.64) | (106.34) | 14.63 | (35.91) | |
| Other line items | |||||
Quick Ratio |
1.01 | 0.41 | 2.07 | 13.64 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(36.80) | (41.84) | (16.73) | (3.08) | |
Capex per Share |
(0.27) | (0.02) | 0.00 | 0.00 | |
Average Payables |
2.51 | 2.56 | 4.20 | 3.20 | |
Average Assets |
118.21 | 104.00 | 66.86 | 120.60 | |
Average Common Equity |
23.00 | (2.78) | 17.13 | (11.79) | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates